CareDx surges on Medicare win, Naveris deal, and raised guidance
Medicare finalizes coverage for transplant tests Medicare locked in coverage for CareDx's AlloSure, AlloMap, and AlloSeq transplant rejection tests, effective August 30, 2026. This removes a big payment uncertainty, making it easier for doctors to order the tests and for CareDx to get paid, which sent the stock up over 35%.
This is the single biggest new regulatory catalyst that directly boosts revenue visibility and drove the period's sharpest price move.
Acquires Naveris for $260 million, enters oncology CareDx bought Naveris for $160 million upfront plus up to $100 million in milestone payments, adding NavDx—a Medicare-covered blood test for HPV-related cancers. This opens a new $12 billion market and is expected to add revenue immediately, giving the company a second growth engine beyond transplant care.
This is a major strategic expansion that diversifies revenue and was a key new event in the period.
Q2 revenue jumps 52%, full-year guidance raised CareDx reported second-quarter revenue of $132 million, up 52% from a year ago, and more than tripled adjusted net income to $20 million. Management raised full-year revenue guidance to $490–500 million and EBITDA to $66–78 million, signaling strong demand for its transplant monitoring tests.
This is the latest hard financial proof that the business is accelerating, directly supporting a higher stock price.